{"id":"axa1125","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AXA1125 works by modulating amino acid metabolism and restoring dysregulated metabolic pathways associated with liver disease and metabolic dysfunction. The therapeutic approach targets the underlying metabolic imbalances rather than a single molecular target, aiming to improve hepatic function and reduce fibrosis progression.","oneSentence":"AXA1125 is a composition of amino acids and metabolites designed to restore metabolic balance and improve liver function in patients with metabolic dysfunction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:43.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-alcoholic fatty liver disease (NAFLD)"},{"name":"Non-alcoholic steatohepatitis (NASH)"}]},"trialDetails":[{"nctId":"NCT05152849","phase":"PHASE2","title":"Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection","status":"COMPLETED","sponsor":"Axcella Health, Inc","startDate":"2021-12-15","conditions":"Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection","enrollment":41},{"nctId":"NCT04880187","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis","status":"UNKNOWN","sponsor":"Axcella Health, Inc","startDate":"2021-05-07","conditions":"Non Alcoholic Steatohepatitis (NASH)","enrollment":273},{"nctId":"NCT04073368","phase":"NA","title":"Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"Axcella Health, Inc","startDate":"2018-12-03","conditions":"NAFLD","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AXA1125","genericName":"AXA1125","companyName":"Axcella Health, Inc","companyId":"axcella-health-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AXA1125 is a composition of amino acids and metabolites designed to restore metabolic balance and improve liver function in patients with metabolic dysfunction. Used for Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}